Should Generalized Immunosuppression or Targeted Organ Treatment be the Best Principle for Overall Management of Systemic Lupus Erythematosus?

Research output: Contribution to journalReview article

Abstract

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease, and standard therapy algorithms include the use of agents with generalized immunosuppressive effects. The outcomes for SLE patients have been markedly improved by this approach. However, the concept that involved organs might be targeted for treatment in an individual patient has potential to provide further benefits, offering enhanced efficacy and fewer off-target effects. This review considers how two of the most commonly involved organ systems in SLE, skin and kidney, might be targets for new therapeutic approaches based on knowledge of underlying mechanisms of disease.

Original languageEnglish (US)
Pages (from-to)369-377
Number of pages9
JournalRheumatic Disease Clinics of North America
Volume45
Issue number3
DOIs
StatePublished - Aug 1 2019

Fingerprint

Systemic Lupus Erythematosus
Immunosuppression
Immunosuppressive Agents
Autoimmune Diseases
Therapeutics
Kidney
Skin

All Science Journal Classification (ASJC) codes

  • Rheumatology

Cite this

@article{b5b75c5a10b84e9498c416917689944f,
title = "Should Generalized Immunosuppression or Targeted Organ Treatment be the Best Principle for Overall Management of Systemic Lupus Erythematosus?",
abstract = "Systemic lupus erythematosus (SLE) is a systemic autoimmune disease, and standard therapy algorithms include the use of agents with generalized immunosuppressive effects. The outcomes for SLE patients have been markedly improved by this approach. However, the concept that involved organs might be targeted for treatment in an individual patient has potential to provide further benefits, offering enhanced efficacy and fewer off-target effects. This review considers how two of the most commonly involved organ systems in SLE, skin and kidney, might be targets for new therapeutic approaches based on knowledge of underlying mechanisms of disease.",
author = "Nancy Olsen",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.rdc.2019.04.004",
language = "English (US)",
volume = "45",
pages = "369--377",
journal = "Rheumatic Disease Clinics of North America",
issn = "0889-857X",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Should Generalized Immunosuppression or Targeted Organ Treatment be the Best Principle for Overall Management of Systemic Lupus Erythematosus?

AU - Olsen, Nancy

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Systemic lupus erythematosus (SLE) is a systemic autoimmune disease, and standard therapy algorithms include the use of agents with generalized immunosuppressive effects. The outcomes for SLE patients have been markedly improved by this approach. However, the concept that involved organs might be targeted for treatment in an individual patient has potential to provide further benefits, offering enhanced efficacy and fewer off-target effects. This review considers how two of the most commonly involved organ systems in SLE, skin and kidney, might be targets for new therapeutic approaches based on knowledge of underlying mechanisms of disease.

AB - Systemic lupus erythematosus (SLE) is a systemic autoimmune disease, and standard therapy algorithms include the use of agents with generalized immunosuppressive effects. The outcomes for SLE patients have been markedly improved by this approach. However, the concept that involved organs might be targeted for treatment in an individual patient has potential to provide further benefits, offering enhanced efficacy and fewer off-target effects. This review considers how two of the most commonly involved organ systems in SLE, skin and kidney, might be targets for new therapeutic approaches based on knowledge of underlying mechanisms of disease.

UR - http://www.scopus.com/inward/record.url?scp=85066070176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066070176&partnerID=8YFLogxK

U2 - 10.1016/j.rdc.2019.04.004

DO - 10.1016/j.rdc.2019.04.004

M3 - Review article

C2 - 31277750

AN - SCOPUS:85066070176

VL - 45

SP - 369

EP - 377

JO - Rheumatic Disease Clinics of North America

JF - Rheumatic Disease Clinics of North America

SN - 0889-857X

IS - 3

ER -